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Allogeneic hematopoietic stem cell transplantation (AHSCT) is a curative treatment for 
a wide variety of hematological diseases. In 30% of the cases, a geno-identical donor 
is available. Any other situation displays some level of human leukocyte antigen (HLA) 
incompatibility between donor and recipient. Deleterious effects of anti-HLA immuniza-
tion have long been recognized in solid organ transplant recipients. More recently, anti-
HLA immunization was shown to increase the risk of primary graft failure (PGF), a severe 
complication of AHSCT that occurs in 3–4% of matched unrelated donor transplantation 
and up to 15% in cord blood transplantation and T-cell depleted haplo-identical stem cell 
transplantation. Rates of PGF in patients with DSA were reported to be between 24 and 
83% with the highest rates in haplo-identical and cord blood transplantation recipients. 
This led to the recommendation of anti-HLA antibody screening to detect donor-specific 
antibodies (DSA) in recipients prior to AHSCT. In this review, we highlight the role of 
anti-HLA antibodies in AHSCT and the mechanisms that may lead to PGF in patients 
with DSA, and discuss current issues in the field.
Keywords: donor-specific antibodies, HLA antigens, allogeneic hematopoietic stem cell transplantation, graft 
failure, single antigen flow bead assay
inTRODUCTiOn
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a life-saving procedure for various 
hematological and immunological conditions. Nowadays ~30% of AHSCT procedures are per-
formed with human leukocyte antigen (HLA)-identical siblings. Any other situation displays some 
level of HLA incompatibility between donor and recipient, even in 10/10 matched unrelated donors 
where a mismatch for HLA-DPB1 and/or DRB3, B4, or B5 is present in 80% of the cases. Deleterious 
effects of anti-HLA immunization have long been recognized in solid organ transplantation (1–3). 
More recently, anti-HLA immunization was shown to increase the risk of graft failure in AHSCT. 
For this reason, it is now strongly recommended to screen recipients for anti-HLA donor-specific 
antibodies (DSA) before AHSCT. In this review, we outline the role of anti-HLA antibodies in 
AHSCT and discuss current issues in the field.
TeCHniQUeS FOR HLA AnTiBODY DeTeCTiOn 
AnD iDenTiFiCATiOn
Complement-dependent lymphocytotoxicity (CDC) tests that were used initially have been widely 
replaced by bead-based assays, such as the single antigen flow bead (SAFB) assays that are more 
TABLe 1 | Studies of DSA impact in different settings in AHSCT.
Reference Patients (n) Stem cell source Conditioning Anti-HLA% DSA% Graft failure with/without DSA
Spellman et al. (34) 115 Mismatched unrelated RIC ND 9 24 versus 1%
Ciurea et al. (36) 592 10/10 and 9/10 unrelated MACorRIC 19.6 1.4 37.5 versus 2.7%
Yoshihara et al. (39) 79 Haplo-identical RIC 20.2 14 27 versus 3%
Ciurea et al. (36) 24 Haplo-identical RIC ND 21 60 versus 5%
Chang et al. (40) 345 Haplo-identical MAC 25.2 11.3 61% (MFI>10,000) versus 3.2%
Ciurea et al. (36) 122 Haplo-identical Non-specified ND 18 32 versus 4%
Takanashi et al. (41) 386 Single CBU MAC 23.1 5 83 versus 32%
Cutler et al. (42) 73 Double CBU MACorRIC ND 24 57 versus 5.5%
Ruggeri et al. (43) 294 Single and double CBU RIC 23 5 81 versus 44%
Yamamoto et al. (44) 175 Single CBU MACorRIC 39.4 ND 50% if anti-HLA-C, DP, DQ, 
DRB1/2/3 versus 16%
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sensitive and resolutive (4). This technique allows antigen-specific 
and even allele-specific antibodies to be identified, using fluo-
rescent micro-spheres each coated with a unique HLA variant/
allele. Each bead subpopulation has a unique color resulting from 
the mixture of two fluorochromes, all the beads from the same 
class being mixed together in a multiplex approach. Currently, 
a panel of nearly 100 class I alleles and quite as many for class 
II, can be analyzed with minute serum amounts in less than 2 h. 
Serum is incubated with the beads, unbound serum components 
are removed through washing, and a phycoerythrin-labeled anti-
human IgG is added to identify the HLA alleles recognized by 
serum antibodies thanks to bead fluorescent coding. Reactivity 
is measured by Luminex-based technology, using a software 
program for subtracting background fluorescence of a negative 
control serum, and is reported as a mean fluorescence intensity 
(MFI) value. This technique is much more sensitive than the 
CDC approach, and slightly more than the classical cell-based 
flow cytometry assay. It, therefore, allows very weak antibodies 
to be identified, which were not detectable before. This method 
measures antibody strength, resulting from the concentration 
of the antibody in the serum combined with antibody affinity/
avidity for the antigen. After nearly 10  years of use, it is still 
not clear in organ transplantation what the clinically relevant 
threshold is, as a deleterious clinical impact has been reported 
at very low MFI (in the 500 range) for kidney transplantation 
(5). This technique has other limitations, besides its high costs: 
false-positive reactions possibly caused by co-purified irrelevant 
antigens, or high level of background reactivity in some patients. 
Another potential issue is complement interference, the so-called 
“prozone” effect, that is due to downstream C4- and C3-derived 
complement activation products that mask the recognition site 
of the PE-labeled anti-human IgG conjugate and impairs its 
binding. This can lead to underestimating anti-HLA antibody 
strength, especially for the strongest ones that would need to be 
at least detected, if not correctly estimated through their MFI 
levels. This phenomenon is avoided by preventing complement 
activation though pre-treatment of serum with EDTA, DTT, or 
heat, which knock down the complement classical pathway at 
the initial step involving the calcium-dependent C1 complex. 
Despite these downsides, SAFB assays have revolutionized the 
field, by allowing the precise identification of antigenic targets for 
anti-HLA antibodies, a goal that could not be technically reached 
before their advent.
ORiGin AnD PRevALenCe OF  
AnTi-HLA AnTiBODieS
“Natural” anti-HLA antibodies can exist in healthy, non-trans-
planted, non-transfused, non-parous individuals, at a prevalence 
estimated to be between <1 and 5% (6, 7). Some “natural” antibod-
ies are reactive against denatured or cryptic HLA epitopes that are 
normally hidden in the well-conformed native molecule, whereas 
others are reactive against native epitopes. Natural antibodies 
are considered as resulting from cross-reactions with common 
environmental antigens encountered by individuals all along their 
lives. Antibodies reactive against denatured epitopes interact with 
HLA molecules that are ill-configured because of natural instabil-
ity or due to procedures used to produce, isolate, and adsorb the 
antigen on the beads (8). Of note, some studies reported on a much 
higher rate of this kind of allo-immunization, reaching up to 63% 
in non-parous individuals (9). This discrepancy may be explained 
by different techniques used in these studies and/or variable cut-
off values for positivity or different bead engineering (10).
Besides natural antibodies, main causes of anti-HLA antibody 
development are pregnancy, blood product transfusion, and pre-
vious transplantation. The incidence of anti-HLA immunization 
through platelet transfusion was strongly decreased by leukocyte 
depletion of blood products: in a large trial, it plummeted from 
45% in controls to 17% in non-parous patients who received 
leukocyte-depleted platelets (11). However, leukocyte reduction 
did not solve the issue of allo-immunization related to red blood 
cell transfusion. The rate of allo-immunization in transfused 
non-parous individuals who received leukocyte-depleted red 
blood cells was not reduced in three randomized control trials 
(12–14): the allo-immunization rate ranged from 10% in low-risk 
patients to over 50% in females with prior pregnancy. In patients 
suffering from hematological diseases, anti-HLA immunization 
ranges from 19.6 to 39.4% (Table 1).
iMMUniZATiOn AGAinST DOnOR HLA 
MOLeCULeS iS ASSOCiATeD wiTH 
PRiMARY GRAFT FAiLURe in AHSCT
Studies in the early 2000s associated detection of complement-
fixing antidonor antibodies in the recipient by cross-match test 
with an increased risk of AHSCT graft failure (15, 16). Although 
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one case report mentioned the occurrence of graft failure related 
to post-transplantation DSA acquisition (17), pre-transplant DSA 
but not de novo post-transplantation DSA have been correlated to 
primary graft failure (PGF). PGF includes graft rejection, defined 
by the inability to achieve a neutrophil count of 0.5 g/l for three 
consecutive days at day 28 post transplantation in the absence of 
donor hematopoiesis. It also includes poor graft function that is 
a failure to achieve adequate blood counts (neutrophils >0.5 g/l, 
hemoglobin >8 g/dl or platelets >20 g/l) for three consecutive 
days in the presence of complete donor hematopoiesis (18, 19). 
PGF is a severe complication occurring in 3–4% of matched unre-
lated donor transplantation and in up to 15% of cord blood and 
T-cell depleted haplo-identical AHSCT (20, 21). This complica-
tion considerably increases the early non-relapse mortality after 
allogeneic stem cell transplantation (22–25). The mechanisms are 
little known since only few studies have addressed them.
MeCHAniSMS OF GRAFT 
FAiLURe in AHSCT
Mechanisms of alloantibody generation and effector functions 
have been well studied in solid organ transplantation (26). Studies 
that investigated the mechanisms of AHSCT graft rejection in 
murine models showed the dominance of humoral immunity in 
major histocompatibility complex (MHC) allosensitized mice. 
Passive transfer of serum from sensitized mice was sufficient to 
induce rejection in naïve recipients (27). Other authors showed 
that antibody-mediated rejection in primed recipients was 
far more rapid than T-cell-mediated rejection in non-primed 
recipients (28). Importantly, this study suggested that antibody-
dependent cell-mediated cytotoxicity (ADCC) was the primary 
mechanism of rejection: allosensitized FcGR−/− recipients did not 
reject their grafts. In human, complement activation has long been 
known in donor-sensitized patients in solid organ transplanta-
tion, through the historic complement-dependent cytotoxicity 
cross match and the deposited C4d staining in biopsies that are 
hallmarks of humoral rejection, and more recently through the 
negative impact of C1q binding (29) or C3d binding (30) DSA in 
SAFB assays. Whether it also represents a significant mechanism 
of rejection in AHSCT remains unclear. However, recently, a 
study showed that patients with C1q-binding DSA pre-existing 
before AHSCT were at higher risk for PGF (31).
The consequence on hematopoietic stem cells was demon-
strated in vitro: CD34 + stem cells incubated in the presence of 
complement and anti-class I or anti-HLA-DR, but not anti-HLA-
DQ antibodies, were not capable of differentiating into lineage 
producing colonies (32). Anti-HLA-DP antibodies were shown in 
another study to have a modest (30%) effect on human myeloid, 
erythroid or multipotential progenitors but no direct impact on 
CD34 + cells was demonstrated (33).
iMPACT OF DSA in DiSTinCT 
HeMATOPOieTiC STeM CeLL 
TRAnSPLAnTATiOn SeTTinGS
Approximately 30% of patients in need for AHSCT have a HLA 
geno-identical donor. If not, transplantation is performed with 
HLA-compatible unrelated donors, or alternative sources of 
hematopoietic stem cells, such as HLA-incompatible unrelated 
donors, cord blood, and, increasingly, haplo-identical donors. 
Table  1 shows the frequency of pre-transplant anti-HLA and 
DSA in AHSCT recipients, and the consequences on graft failure, 
according to the stem cell source.
impact of DSA in the Matched 
Unrelated Donor Setting
In the matched unrelated donor setting in Europe, HLA typing 
is performed for A, B, C, DRB1, and DQB1 loci and a 10/10 or 
at least 9/10 match is sought for. By contrast, in the US, DQB1 
typing is not required, and a compatibility of 8/8 is considered 
as sufficient. In both continents, HLA-DPB1 matching is not 
required.
In one early study on 60 patients undergoing one-mismatch 
intra-familial transplantation or unrelated donor transplantation, 
the presence of anti-HLA antibodies detected by serum cross-
match technique was associated with a significantly increased 
risk of graft failure when the cross-match test was positive (16). 
In another study, the authors retrospectively studied 115 patients 
who had received myeloablative conditioning (MAC) with at 
least one mismatch among A, B, C, DRB1, DQB1, or DPB1 loci 
(34). When comparing the frequency of pre-graft DSA in the 
no-engraftment group versus the engraftment group, they found 
that 24% of patients who did not engraft had DSA pre-transplant 
versus 1% in patients who did engraft.
To date, the importance of anti-HLA-DPB1 immunization 
is still debated, especially since DPB1 compatibility is not con-
sidered when allocating transplants. As a consequence, 80% of 
transplants are performed across a HLA-DPB1 mismatch (35). 
In a prospective study, the authors studied 592 recipients of 
unrelated transplants (85% of 10/10 and 16% of 9/10 matched 
transplants) who received MAC. DSA were present in 1.4% of 
patients, all directed against HLA-DPB1. Graft failure occurred 
in 3.2% of cases. This event occurred in 2.7% of patients without 
DSA compared with 37% of patients with DSA (36). Very little is 
known about the impact of DP expression levels on hematopoi-
etic stem cells on risk of PGF. Interestingly, in this study, HLA 
DP expression was significantly lower on CD34+ from peripheral 
blood than from BM, suggesting that risk of PGF might be less 
important when grafts are obtained from peripheral blood. 
However, in a retrospective study on 2716 patients who received 
matched unrelated and mismatched unrelated AHSCT, the 
engraftment rate was not different in patients receiving stem cells 
from BM versus peripheral blood (3.7 and 3.9% of graft failure, 
respectively, p = 0.83) (37).
impact of DSA in the Haplo-identical 
Transplantation Setting
In haplo-identical transplantation, only one gene for each 
locus is matched between donor and recipient. This procedure 
is undergoing a rapid development because it offers the pos-
sibility of having a donor for AHSCT to nearly every patient. 
Thus, it was crucial to investigate the impact of DSA in this 
setting. In a retrospective case-control study, which included 24 
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patients who received T-depleted haplo-identical transplanta-
tion with reduced intensity conditioning (RIC), the incidence 
of pre-transplant DSA was 21%. Risk of graft rejection was 
increased from 5% in the non-DSA group to 60% in the group 
with DSA (38). More recent studies were done in T-cell replete 
haplo-identical transplantation settings. The authors reported 
that among 79 patients transplanted with RIC, 14% had DSA, 
and graft failure was reported in 27% among them versus 3% 
in the no DSA group (39). Larger studies confirmed that the 
presence of DSA was associated with PGF. In a study on 345 
patients with MAC conditioning, 11.3% had DSA and presence 
of DSA was associated with PGF in multivariate analysis (40). 
In a study on 122 patients, 18% of patients had DSA before 
transplantation and among them, 7 (32%) experienced graft 
failure (31).
impact of DSA in the Umbilical Cord 
Blood Transplantation Setting
In this setting, only HLA-A, -B, and -DRB1 matching is searched 
for, but not absolutely required. An effect on graft rejection 
of antibodies against these antigens when mismatched was 
found in a study on 386 adult patients with MAC conditioning. 
Importantly, this study was done with single cord blood unit 
(CBU), which on its own probably partly explains the high rates 
of graft failure (83% in group with DSA versus 32% in group 
without DSA) (41). In a study on 73 patients who received 
double CBU with mostly RIC conditioning, PGF occurred in 
18% of patients who had DSA against one CBU and in 57% 
of patients who had DSA against both CBU versus only 5.5% 
in the no DSA group (42). In another study performed on 
294 patients with RIC who received one or 2  CBU, engraft-
ment rate at day 60 was 81 versus 44% in the no DSA group 
and TRM was also increased from 32 to 43% in patients with 
DSA (43). The impact of DSA against HLA-C, -DP, -DQ, and 
-DR3/4/5 was specifically investigated in another study on 175 
patients receiving single CBU, showing that engraftment rate 
was inferior in HLA-mismatched patients who had anti-HLA 
antibodies against HLA-C, -DP, DQ, and -DRB3/4/5 compared 
to patients without anti-HLA antibodies or to patients who had 
antibodies against HLA-A, -B, or -DRB1 but no DSA. Because 
typing of HLA-C, -DP, -DQ, and -DRB3/4/5 loci was lacking, the 
authors hypothesized that unrecognized DSA were responsible 
for the lower engraftment rates (44).
iMPACT OF DSA MFi STRenGTH
Several studies have shown that higher MFI of DSA were 
associated with an increased rate of graft failure (36, 38–40, 
42, 43). However, there is no consensus on a clear cut-off 
above which the DSA is likely to cause graft failure. In a 
study, the authors suggested the clinically significant cut-off 
could be the positivity of the SAFB C1q assay (31), which is 
grossly correlated with antibody MFI strength in the IgG assay 
setting, in the field of organ transplant recipients (45–48). 
However, larger studies are needed to better determine a clear 
cut-off value.
ROLe OF DOnOR-DeRiveD HLA 
AnTiBODieS in AHSCT ReCiPienTS
Very little is known regarding the role of donor-derived anti-
HLA antibodies. Donor-derived antibodies might emerge in 
recipients of AHSCT because the graft contains memory B cells 
that can differentiate into plasma cells that could be specific 
for a given recipient HLA determinant. One study reported 
the frequent detection of anti-HLA antibodies in patients who 
underwent AHSCT from anti-HLA antibody-positive donors 
(49). One group screened 127 donors for anti-HLA antibod-
ies. Seven donors were anti-HLA antibody positive. Among 
the seven patients who received AHSCT from these donors, 
four subsequently became anti-HLA antibody positive, with 
antibodies that closely resembled the antibodies found in their 
donors. The antibodies had MFI that peaked between Days 20 
and 30 in all patients, then decreased and disappeared before 
Day 100 (50). In a case report about two patients who received 
haplo-identical transplantation from anti-HLA antibody donors, 
the recipients became anti-HLA antibody positive and stayed 
positive for less than a year (51). In these studies, the antibod-
ies were not recipient specific. The impact of recipient-specific 
compared to non-recipient-specific antibodies is not known. In 
a recent study, the authors studied a cohort of 82 HLA class II 
mismatched unrelated AHSCT donor-recipient pairs (52). In 
this cohort, 26 donors (32%) had at least one anti-HLA class II 
antibody detected in peripheral blood. The recipients of a graft 
from an anti-class II immunized donor had a significantly higher 
2-year cumulative incidence of a first episode of either acute or 
chronic graft-versus-host disease (88 versus 67%), suggesting 
that donor immunization against foreign HLA antigens could be 
a new parameter to consider for predicting the risk of GVHD 
after HLA-mismatched unrelated HSCT. However, this observa-
tion needs to be confirmed on a larger cohort and the impact of 
recipient-specific antibodies to be studied.
STRATeGieS FOR DSA ReDUCTiOn 
BeFORe TRAnSPLAnTATiOn
The most widely used strategy in case of pre-transplant DSA 
is to identify and select another donor. Since this is not always 
possible, several reports mentioned successful strategies to 
reduce plasma DSA strength prior to transplantation. These 
reports most often describe single patients or very small series 
and are possibly biased since failure to reduce DSA might 
have remained unreported in many cases. The most frequent 
strategy involved B-lymphocyte depletion with rituximab and 
plasma exchanges (38, 39) sometimes combined with high-
dose intravenous immune globulins or infusion of irradiated 
donor lymphocytes (31). The reduction of DSA with these 
treatments was variable but often only partially effective, treat-
ment efficacy being likely related to pre-existing DSA levels. 
Another strategy involved transfusion of platelets bearing 
HLA antigens corresponding to DSA, which induced rapid 
and significant DSA reduction (39, 53). This strategy could be 
associated with rituximab in order to reduce DSA-producing 
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B-lymphocytes (53). Lastly, bortezomib associated with 
dexamethasone was tested in one patient with a moderate DSA 
reduction (39).
There is no consensus regarding the appropriate titer at which 
a strategy of antibody reduction should be applied in HSCT, as 
there is no consensus on the clinically relevant threshold for 
DSA strength. There is no consensus in organ transplantation 
either, but recent reports strongly suggest that DSA clinical 
impact occur earlier as its serum strength increases at time of 
transplantation (29, 47) In the AHSCT setting, the situation 
is different, because as soon as complete donor chimerism is 
reached, DSA production by recipient B cells disappears. For 
this reason, the threshold for DSA levels that might require 
therapeutic intervention could be different between both 
settings.
In conclusion, although the mechanisms underlying the asso-
ciation between anti-HLA DSA and graft rejection in AHSCT are 
unclear, numerous studies report on a deleterious effect of DSA on 
AHSCT engraftment, without clearly identifying innocuous HLA 
loci. Further studies are needed, especially regarding the cut-off 
of MFI values that have clinical consequences on graft survival, 
and the impact of anti-DP antibodies, since mismatches are most 
frequent in this locus even for 10/10 matched unrelated donors.
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